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Abstract
Sulfonylhydrazines are a class of DNA alkylating drugs which also produce
carbamoylating activity in situ. The carbamoylating species is of significance because it
has shown to inhibit important thiol-containing enzymes such as glutathione reductase
(GR) and thioredoxin reductase (TrxR). TrxR catalyzes dithiol-disulfide exchange
reactions on thioredoxin (Trx), which in turn catalyzes other reductive processes such as
deoxyribonucleotide biosynthesis. In this study, we demonstrate that TrxR activity is
strongly inhibited by the anticancer prodrug Cloretazine both in purified form and in
leukemia cell lysates. This inhibition is specific to the carbamoylating activity of
methylisocyanate (MiC). In contrast, another important oxidoreductase, glutathione
reductase (GR), was inhibited in purified form, but showed little susceptibility to
Cloretazine in the cellular context. These results suggest the mode of inhibition against
TrxR and GR differs inside of cells. Due to the overexpression of TrxR in cancer cells
and its role in DNA metabolism, inhibiting TrxR may be important to the activity of the
anticancer agent Cloretazine.
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Introduction:
As cancer research evolves, cytotoxic chemotherapy remains one of the most
effective options for cancer patients. The use of cytotoxic agents to fight disease began in
the 1940’s with the discovery of nitrogen mustard [1]. Research involving nitrogen
mustard established the principle that drugs could be administered to induce tumor
suppression. The creation of national programs, including the National Cancer
Chemotherapy Service Center, led to new developments in animal models, cell lines, and
transplantable solid tumors [1, 2]. One of the most important advances in chemotherapy
was improvements in screening methodology. High throughput screening allowed
researchers to identify anticancer agents at a faster pace. Promising drugs became defined
as metabolically stable, well adsorbed from oral administration, and containing a
favorable toxicity profile [1]. New understandings in cell biology identified cellular
activities specific to cancer cells. Cell-cycle proteins, signaling molecules, and growth
factors all became new targets for chemotherapy [1, 2]. Unfortunately, most of the
anticancer agents designed never make it into clinical use due to lack of efficacy and high
toxicities [2, 3]. Understanding how these toxicities arise may help to design more
successful agents and to increase the number of viable drugs.
Cancer cells rapidly metabolize and proliferate compared to normal actively
dividing cells. The fast proliferation requires continuous DNA replication and
metabolism. Thus, tumor cell DNA is a primary target for many cytotoxic agents [4, 5].
DNA alkylating agents are some of the most effective types of chemotherapeutic drugs
[5]. These anticancer drugs are responsible for significant increases in survival of many
cancer patients [5]. Alkylating agents are able to alkylate a specific position of DNA [4].
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Events that directly damage DNA are extremely cytotoxic for cells, as alkylated DNA
can inhibit or prevent gene transcription or DNA replication. Although these agents are
used to fight cancer, they often prove toxic or carcinogenic. Alkylating drugs are not
completely specific to cancer cells; they can cause adverse effects for other actively
dividing cells [4, 5].
Nitrosoureas are one class of chemotherapeutic compounds which generate DNA
alkylating species. BCNU (1, 3-bis [2-chloroethyl]-2-nitrosourea), a common nitrosourea,
is an important multi functional alkylating drug clinically used to treat brain cancers [6].
This anticancer compound generates species with chloroethylating and carbamoylating
activity [7, 8]. BCNU also generates species with vinylating, hydroxyethylating, and
aminoethylating activity [8]. These extra species add to the toxicity of BCNU and have
no therapeutic benefit (Fig. 1) [8].

Figure 1: Summary of Reactive Species Produced by BCNU.

The cross-linking activity of BCNU is believed to be the primary cause of its
cytotoxicity [9]. Chloroethylation of the O6 position of guanine initiates the formation of
4

cross links by the loss of the halide and formation of O6N1-ethanoguanine followed by a
reaction with a complementary cytosine to make a GC crosslink [7]. The carbamoylating
activity is a function of 2-chloroethyl isocyanate (CEiC). Isocyanates capable of
carbamoylation are able to react with thiols, such as those on proteins. Specifically,
BCNU has been shown to inhibit thiol-containing enzymes such as glutathione reductase,
thioredoxin reductase, and ribonucleotide reductase in both purified and cellular forms
[8].
Cloretazine,

(1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-

[(methylamino)carbonyl]hydrazine; VNP40101M) is a sulfonylhydrazine anti-cancer
compound which has shown broad spectrum antineoplastic activity in preclinical models
[8]. Cloretazine is currently being used in clinical trials for blood and brain cancers,
notably glioma and acute myeloid leukemia [9, 10]. In situ Cloretazine generates two
reactive

species,

1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine

(90CE)

and

methylisocyanate (MiC) (Fig. 2), which are attributed to the Cloretazine’s anti-cancer
activity [8, 9, 10].

Figure 2: Structure and activation of Cloretazine yielding species with alkylating and
carbamoylating activities
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90CE is an alkylating species that chloroethylates DNA at the O6 position of
guanine, similar to the chloroethylation by BCNU [9]. This reaction forms a cross-link
with the complementary cytosine, resulting in an extremely cytotoxic event for the cell.
The other species generated from Cloretazine, methylisocyanate, can carbamoylate
sulfhydryl groups, such as those on cysteine residues in proteins [9]. 90CE is also an
analog of Cloretazine that chloroethylates, but does not carbamoylate. Similarly,
101MDCE is also an analog of Cloretazine that has the opposite activity (Fig. 3).
Cloretazine is especially interesting given the lack of toxic side effects relative to BCNU,
as Cloretazine does not generates species with vinylating, hydroxyethylating, and
aminoethylating activity (Fig. 1) [9, 10].

Figure 3: Chemical structure of sulfonylhydrazine prodrugs 101MDCE and 90CE.

The two species produced by Cloretazine, 90CE and methylisocyanate, have a
synergism that gives the drug exceptional anticancer activity [9]. The two pathways in
which the species work are connected in a way that makes the drug more effective then
either species alone. The anticancer activity of Cloretazine is mostly due to cytotoxic
cross-linking of DNA. Cloretazine has been shown in cell-free systems to yield more
cross-links than the similar agent BCNU [10]. The synergism is perhaps explained by
6

effects of carbamoylation on the enzymes of DNA repair and metabolism. A study
involving

Cloretazine

and

the

direct

repair

protein

O6-

alkylguanine-DNA-

alkyltransferase (AGT) also showed the synergism between 90CE and methyl
iscocyanate [8]. AGT is responsible for restoring the damaged O6 guanine monoaducts to
its native state [8]. For experiments conducted without AGT present, 90CE and
Cloretazine generated the same number of DNA cross links [8]. However, when AGT
was present, Cloretazine created a higher number of cross links then 90CE alone,
suggesting the synergism of the carbamoylating activity of Cloretazine [8].
In an effort to better understand the cytotoxic mechanism of Cloretazine, it may
be useful to examine the effects of the drug on important enzymes of DNA metabolism.
Thioredoxin reductase (TrxR) is an enzyme involved in many important cellular
processes, including antioxidant defense, redox regulation, and cell growth [11, 12, 13].
TrxR belongs to the class of disulfide oxidoreductases, which work to maintain certain
proteins of the cell in reduced states [11]. This class of enzymes may be particularly
sensitive to drugs with carbamoylating activity because of the dithiol/disulfide active site.
There are three known isoenzymes known that are expressed in different tissues [13]. In
this case, TrxR-1 or cytosolic TrxR is of interest. TrxR works by reducing thioredoxin
(Trx) with electrons provided by NADPH; reduced Trx then provides the reducing
equivalents for other enzyme catalyzed reactions such as that of ribonucleotide reductase
(Fig. 4) [12].
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Figure 4: Function of TrxR/Trx system in the cell.

Given their high metabolic levels, malignant cells tend to overexpress TrxR [13].
Previous work in our laboratory has shown that agents with carbamoylating activity
inhibit purified TrxR from rat liver (Fig. 5) (unpublished data).

Figure 5: Inhibition of Purified TrxR by agents with carbamoylating activity (unpublished data).

Of all the enzymes thus far exposed to Cloretazine, TrxR is the most sensitive to the drug
(unpublished observation). Inhibition concentrations (IC50 values) of carbamoylating
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agents against TrxR were in micromolar range (Fig. 5). Most other enzymes tested have
had markedly higher IC50 values (unpublished observation). Typically enzyme inhibitors
are only considered viable pharmaceutical agents with nanomolar IC50 values. However,
micromolar concentrations are clinically relevant for Cloretazine, because up to 100 μM
Cloretazine has been measured in patients [7]. Interestingly, one study reported that a
similar oxidoreductase, glutathione reductase, is also inhibited by Cloretazine in purified
form, but further work showed that the drug was unable to inhibit the enzyme in a
cellular environment [9]. This provides the basis of the research examining Cloretazine’s
inhibition of cellular Trx-R.
Using mammalian cell culture and a TrxR enzyme assay, the activity of TrxR was
measured under varying concentrations of the studied agents. L1210 murine leukemia
cells treated with the drugs Cloretazine, BCNU, 90CE, and 101MDCE were harvested,
lysed and clarified. Due to TrxR’s wide substrate potential, the enzyme can reduce 5,5dithiobis-(2-nitrobenzoic acid) (DTNB), which is colorless, but turns yellow upon
reduction to 2-nitro-5-mercaptobenzoic acid. Thus, the enzymatic activity of cellular
TrxR from L1210 lysate can be measured spectrophotometrically.

Materials and Methods
Enzymes and Biochemicals
Cloretazine, 101MDCE, and 90CE were synthesized, purified, characterized as described
elsewhere and provided by Prof. Alan Sartorelli of Yale University [14]. BCNU was
purchased from Sigma (St. Louis, MO). Stock solutions of drugs were prepared by
dissolving them in dry DMSO to concentrations of 200 mM and storing them at -20°C.
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Dilutions of the respective drugs were also prepared in dry DMSO. Purified TrxR from
rat liver was purchased from Sigma (St. Louis, MO). Bovine Serum Albumin (BSA) was
purchased from Fischer Scientific (Suwanee, GA). Protease Arrest of the protease
inhibitor cocktail was purchased from G Biosciences (St. Louis, MO). ß-nicotinamide
adenine dinucleotide phosphate (NADPH) was purchased from Sigma (St. Louis, MO).
NADPH was prepared by dissolving it in 10 mM Tris-Cl pH 7.4 to a concentration
measured spectrophotometrically at 340 nm using the extinction coefficient 6.22 μM-1
cm-1.

Cell Culture
L1210 murine leukemia cells were cultured in RPMI 1640 medium, supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin, in an atmosphere of 5% CO2 at
37°C. The cells were maintained at densities between 104 to 106 cells/mL.

Preparation of L1210 Cell Lysates

L1210 cells were harvested from cultures containing greater then 108 total cells by
centrifugation (Du Pont Sorvall TC centrifuge) at 1,300 rpm for 5 minutes at room
temperature. The supernatant was removed by aspiration and the cells were then
resuspended in fresh RPMI 1640 medium pre-warmed to 37 °C to give a cell density of 5
x 106cells/mL. 15 mL Falcon tubes containing 3.5 x 107 cells were treated with a given
agent (Cloretazine, 101MDCE, 90CE, BCNU, or DMSO) at a final concentration of 200
μM or 50 μM with 0.1% v/v DMSO. Control cells were also treated with 0.1% v/v
10

DMSO. The samples were incubated at 37° C in 5 % CO2 environment for three hours
with the cap on loosely to allow for gas exchange. The samples were mixed halfway
through the incubation by several gentle inversions. Post-incubation, the cells were
harvested by centrifugation at 1,300 rpm for 5 min as before. Each cell pellet was washed
in 1 mL of 1x phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4, pH [7.4]) and centrifuged again at 1,300 rpm for 5 min at
room temperature as before. The samples were resuspended in 500 μL of lysis buffer (50
mM Tris-Cl pH 7.4, 50 mM EDTA, [1x] Protease Arrest) and then lysed either by
sonication (five cycles at 60% power with a Fisher sonic dismembrator model 300) or
three consecutive freeze/thaw cycles (-70°C/37°C). The lysates were clarified by high
speed centrifugation at 14,000 rpm in a Thermo IEC MicroCL 21 centrifuge for five
minutes at room temperature. The supernatant was removed by aspiration, retained, and
kept on ice.

Cellular TrxR Assay

Lysates were analyzed for TrxR activity with a TrxR assay. 70 μL of TrxR cocktail (100
mM potassium phosphate pH 7.4, 1 mM EDTA pH 8, 5 mM 5,5-dithiobis-(2nitrobenzoic acid (DTNB), 0.3 mM reduced ß-nicotinamide adenine dinucleotide
phosphate (NADPH)) was added to 30 μL of lysate in a 96-well plate. All reactions were
carried out in triplicate. For the negative control, the TrxR cocktail was the same except
for the NADPH was absent and 10 mM Tris-Cl pH 7.4 was added in place. The reaction
progress was monitored by the change in absorbance at 412 nm by the reduction of
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DTNB with a Molecular Devices Spectramax M2 spectrophotomer for 10 minutes at
25°C. Readings were taken every 34 seconds for a total of 18 data points per experiment.
Data were transferred to a Microsoft Excel spreadsheet where the change in absorbance
versus time was calculated for the most linear portion of data. These slope values were
adjusted using the extinction coefficient of DTNB (14150 M-1 cm-1). Enzymatic activity
was normalized to the protein concentration in the lysate sample measured by a Bio-Rad
Protein assay according to a manufacturer’s protocol against a BSA standard curve [15].
Activities were background corrected by subtracting out the negative control activity and
were reported as a fraction of the positive control activity (no agent).

Variable NADPH Assay

L1210 cell lysates harvested without drug exposure were analyzed for TrxR activity with
varying NADPH concentrations in a TrxR cocktail. Five, two-fold serial dilutions of
NADPH were prepared starting at 200 μM (100 μM, 50 μM, 25 μM, 12.5 μM) plus a
sixth well with only buffer (10 mM Tris pH 7.4). 60 μL of TrxR cocktail (100 mM
potassium phosphate pH 7.4, 1 mM EDTA pH 8, 5 mM DTNB) and 10 μL of the
respective NADPH dilutions were added to 30 μL of lysate (in duplicate) to a 96-well
plate. The reaction progress was monitored by the change in absorbance at 412 nm by the
reduction of DTNB with a Molecular Devices Spectramax M2 spectrophotomer for 10
minutes at 25 °C. Readings were taken every 34 seconds for a total of 18 data points.
Vmax points correlating to TrxR activities were analyzed in Excel using Michaelis-Menten
kinetics (Fig. 6) to find the best correlation of substrate concentration and rate.
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Figure 6: Michaelis-Menten equation and adjust equation used to fit the data obtain from the
varying NADPH experiment. * see results section

Results

TrxR Activity
The inhibition of TrxR by Cloretazine, BCNU, 101MDCE, and 90CE was analyzed by
incubating L1210 cells with drug for 3 hours at 37 °C in 5 % CO2. TrxR activity is
dependent on availability of NADPH [8]. Fraction activity of TrxR was calculated by
subtracting out the negative control and taking that as a fraction of the difference of the
positive and negative controls. Cloretazine, BCNU, and 101MDCE inhibited the activity
of cellular TrxR (Fig. 7). 90CE did not inhibit cellular TrxR, showing no effect on the
activity of the enzyme. Lysates from cells treated with 200 μM concentrations of
Cloretazine retained only 8.67 % of the control activity ± 9.8%. Lysates from cells
treated with 200 μM BCNU retained 7.83 % activity ± 13.3 % and 200 μM 101MDCE
retained 34.6 % activity ± 12.4 %. These activities were significantly less than the
activity of cell lysates treated with 200 μM concentrations of 90CE which resulted in
activities of 94.8 % ± 12.0 %. Cell lysates treated with 50 μM concentrations of
Cloretazine retained 49.8 % of the control activity ± 9.62 %. Lysates treated with 50 μM
concentrations of BCNU retained 44.4 % activity ± 7.22 % and lysates treated with 50
μM concentrations of 101MDCE resulted in 57.5 % of the control activity ± 13.4 %.
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These 50 μM concentrations of agents also show significantly lower activities compared
to 90CE which remained unaffected with 86.8 % of the control activity ± 13.8 %. These
results suggest drugs with carbamoylating activity are able to inhibit TrxR in the cellular
context. Cloretazine and BCNU had similar inhibitory effects at both 50 and 200 μM
concentrations, showing no major differences between the two (Fig. 7). 101MDCE, while
able to inhibit TrxR, differed from the other carbamoylating agents in ability to inhibit
TrxR at the 200 μM concentration, but showed similar effects to BCNU and Cloretazine
at 50 μM (Fig. 7). 90CE, a DNA alkylating agent, lacking carbamoylating activity,
showed no ability to inhibit TrxR. Activities around 90 % suggest that the enzyme is still
functional and carrying out biochemical reductions.
1
0.9

Fraction Control Activity

0.8
0.7
0.6
0.5

μM 200
μM 50
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BC NU
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Figure 7: Inhibition of cellular thioredoxin reductase by agents with carbamoylating activities.
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Variable NADPH

By varying the NADPH in experiments measuring the activity of TrxR from cell lysate,
the initial enzyme velocity can be plotted as a function of the concentration of substrate
according to the Michaelis-Menten equation. In the absence of added NADPH, TrxR
activity was still measured. The endogenous concentration of NADPH was extracted
using Michaelis-Menten kinetic principals. Adjusting for the Michaelis-Menten equation
to account for an initial level of NADPH present in the cell, we could solve for the
endogenous concentration of NADPH.

120
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80
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40

20

0
0

50

100

150
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[NADPH]

Figure 8: Michaeis- Menten Plot to calculate the endogenous concentration of NADPH in L1210 cell
lysates
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The red curve (Fig. 8) represents the theoretical curve for the rate of TrxR at a given
concentration of NADPH. The blue curve represents the actual measured data. The data
were fit using the solver tool in Excel. [S]0 was extracted using a least squares fit to the
hyperbolic function. The NADPH concentration was measured to be 9.4 μM. Due to the
dilution of the cells in lysis buffer, it is approximated that this endogenous concentration
of NADPH is closer to 45 μM, which is comparable to literature values of human
erythrocytes [16].

Discussion
A relatively new class of chematherapetuic agents, sulfonylhydrazines has
provided promising results in clinical and preclinical trials. Cloretazine is an anticancer
agent that has shown broad anti-tumor activity in preclinical models [10]. Currently,
Cloretazine is in clinical trials for several cancers, showing significant activity against
acute myeloid leukemia. Single agent trials of Cloretazine have produced remissions in
patients suffering from leukemia [10]. The lack of toxicity makes Cloretazine favorable
for combinatory treatments with other agents [5]. Although the mechanism of the drug is
extremely complex and yet to be fully understood, the chemistry of Cloretazine is
relatively simple. The drug decomposes after base activation to yield two species with
alkylating and carbamoylating activities respectively. Cloretazine owes its anticancer
activity to its ability to cross link DNA by its alkylating species. However, it is believed
that the carbamoylating activity enhances the cytotoxicity of the cross linking through
synergistic mechanisms.
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Along with Cloretazine, nitrosoureas represent a class of cytotoxic agents used in
chemotherapy that generate alkylating and carbamoylating activities. BCNU, also known
as Carmustine, has already proven its clinical usefulness, as it has been used for years to
treat lymphomas and brain tumors [5]. One major difference between Cloretazine and
BCNU is that BCNU decomposes to produce hydroxyethylating, vinylating and
aminoethylating species in addition to the chloroethylating and carbamoylating ones,
which Cloretazine does not. These extra reactive species increase the toxicity of BCNU
and have no therapeutic benefit as they are known to cause carcinogenic and mutagenic
events [5]. These associated toxicities of BCNU promote the search for better DNA
alkylating agents with similar activities.
Another important difference between Cloretazine and BCNU is of the
isocyanates produced by each compound. Cloretazine generates MiC, while BCNU forms
Chloroethyl isocyanate (CEiC). Both are efficient in carbamoylating activity, but CEiC
can be hydrolyzed to form 2-chloroethylamine, which can damage DNA [7]. This
deleterious effect is not found with MiC. The therapeutic superiority of Cloretazine over
BCNU, besides forming more cross links, may also be due to the differences in
isocyanates. As we have discussed, DNA alkylation by chloroethylating has been studied
extensively. However, the activity of isocyanates remains elusive, although recent
evidence suggests a significant role for carbamoylating activity. Further research is
necessary to fully understand the therapeutic benefit and clinical significance of
isocyanates.
The nature of isocyanates with carbamoylating activities provides a class of target
proteins that contain reactive thiols. TrxR is an oxidoreductase containing reactive thiols
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in the form of cysteine residues, with the main function to provide reducing equivalents
for other biochemical reactions. TrxR is also involved in maintaining redox equilibrium
in the cell and plays a role in apoptotic pathways. Interestingly, this important enzyme is
elevated in tumors and malignant tissue, where it supports cell growth and proliferation
[11, 13]. The importance of the TrxR/Trx system in the cell will ultimately lead to serious
effects if TrxR is inhibited. Inhibition of TrxR leads to reduced amounts of Trx to be used
as reducing equivalents. Ribonucleotide reductase, which is dependent on these reducing
equivalents, then loses function, and lower levels of deoxyribonucleotides are produced.
As 90CE alkylates and damages DNA, the cell is then unable to repair the damaged DNA
due to the lack of nucleotides present. It is also critical for the cell to replicate the genetic
material in order to maintain the rapid division. With the decreased concentration of
deoxyribonucletides, the cancer cells will be unable to carry out division and replication,
making Cloretazine effective at blocking tumor growth. Inhibiting TrxR can lead to an
increase in reactive oxygen species (ROS), apoptosis, and a decrease in tumor growth
among other things [13]. The elevated levels of TrxR and the variety of cytotoxic events
provided by inhibiting TrxR make the enzyme a favorable anticancer target.
In previous work, purified TrxR was shown to be inhibited by Cloretazine in a
cell free environment. Here we have shown that under cellular conditions Cloretazine
was also effective in inhibiting TrxR. Not only does Cloretazine inhibit the activity of
TrxR, but it acts to a similar extent as the clinically viable agent BCNU. Surprisingly, a
similar oxidoreductase, glutathione reductase (GR), was shown to be inhibited in purified
form, but not under the cellular context by Cloretazine [9]. BCNU was able to inhibit GR
in both the purified and cellular form. This selective inhibition may be explained by the
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differences in isocyanates generated by the two drugs. Chloroethyl isocyanate (CEiC)
was able to inhibit both TrxR and GR, while MiC inhibited only TrxR. GR could have a
stronger affinity for CEiC than MiC, and is therefore more efficient in a cellular
environment in inhibiting the enzyme. However, the inability of MiC to inhibit GR is
therapeutically beneficial. GR is an extremely important protein involved in antioxidant
defense, primarily in the pulmonary tissues, where reactive oxygen species are constantly
evolved [9]. Inhibition of this enzyme leaves these cells and tissues more sensitive to
toxic and deleterious effects of ROS damage [9]. The therapeutic superiority of
Cloretazine over BCNU is evident from these results. BCNU inhibits both GR and TrxR,
but leads to toxic side effects; here we show that Cloretazine has a similar in vivo
inhibition of TrxR and lacks the toxicity of BCNU.
As an attempt to explain the high background during the experiments, the activity
of TrxR was measured using varying NADPH. The activity at zero added NADPH could
arise from two possibilities. First, there could be a source of cellular NADPH. Second,
another enzyme or molecule could be reducing DTNB. Endogenous NADPH is
reasonable explanation since we used whole cell extracts to analyze TrxR. Normally cells
have pools of NADPH available for reactions, or in this case enough for activity of TrxR
to still be measurable. In order to determine the endogenous level of NADPH, activities
at various concentrations of NADPH were measured. Then using an adjusted MichaelisMenten equation, the initial substrate concentration could be calculated. The levels of
NADPH are slightly elevated, but still comparable to literature values of normal
erythrocytes [16]. This is understandable as cancer cells are rapidly metabolizing
compared to normal proliferating cells and may require more NADPH than usual.
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Another method to test the high background and prove that TrxR is being measured
properly would be to utilize a known inhibitor of TrxR. Using a known inhibitor should
completely knock out the activity of TrxR reducing DTNB at any concentration of
NADPH. This would let us know that we are correctly assuming that TrxR is reducing
DTNB and not something else.
In order to better understand the mechanism of anticancer activity of Cloretazine,
we investigated the inhibitory effects of carbamoylation on the enzyme TrxR in a cellular
environment. The therapeutic benefit of isocyanates still requires further research, but as
studies progress they appear to be important to the cytotoxicity of the respective drugs.
As for Cloretazine, it is more evident that the carbamoylating activity of MiC synergizes
with the cross linking of 90CE through effects of DNA metabolism, ultimately increasing
the cytotoxicity of this prodrug. In this study Cloretazine was able to inhibit cellular TrxR
in almost equal amounts as BCNU, yet Cloretazine lacks the toxic side effects of BCNU,
including inhibition of GR. This could suggest that Cloretazine could eventually replace
BCNU in chemotherapies and expand the therapeutic benefit to the patient.
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